Homology modeling and molecular docking studies for the identification of novel potential therapeutics against human PHD3 as a drug target for type 2 diabetes mellitus by Lanka, Goverdhan et al.
Lanka et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(4):265-273 
 
ISSN: 2250-1177                                                                                  [265]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.07.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Homology modeling and molecular docking studies for the identification of 
novel potential therapeutics against human PHD3 as a drug target for type 2 
diabetes mellitus 
Goverdhan Lanka, Revanth Bathula, Manan Bhargavi, and Sarita Rajender Potlapally* 
Molecular Modeling Laboratory, Department of Chemistry, Nizam College, Osmania University, Basheerbagh, Hyderabad-500001 
 
ABSTRACT 
PHD3 (Prolyl Hydroxylating Domain) 3 protein contains the HRE (Hypoxia Response Element) and plays an important role in regulating HIF 
subunits. The hydroxylating ability of PHD3 of HIF subunits makes PHD3 is a prominent therapeutic target to control type 2 diabetes mellitus. 
The structure based approach is used to design novel molecular entities against PHD3 protein. In this present work, a 3D homology model of 
PHD3 was generated by MODELLER9.9 as the experimental structure of PHD3 is not reported in the protein database.  The 3d structural model 
of PHD3 refined through energy minimization in VMD-NAMD interface. Active site of the target protein is identified by SiteMap module 
(Schrodinger suite), manual correlation technique using ClustalW software and literature studies. The asinex library of chemical structures 
subjected to the molecular docking at the PHD3 active site for the identification of potent inhibitors. The molecules resulted from molecular 
docking prioritized based on their docking score, glide energy. The ligand molecules are further prioritized with a rescoring parameter Prime-
MM/GBSA by calculating binding free energies of final Ligand-Protein complexes. The identified novel leads are further evaluated with ADME 
properties for their druglikeness activity. The overall insights can further expedite for the development of novel molecular entities as potential 
inhibitors against PHD3 in type 2 diabetes mellitus. 
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INTRODUCTION 
Type 2 diabetes mellitus deals with insulin resistance and 
low levels of insulin release by pancreatic beta cells. A state 
of chronic inflammation and beta cell dysfunction induces 
insulin resistance and causes type 2 diabetes mellitus [1, 2]. 
The current major anti-diabetic medications have 
disadvantages which includes efficacy, cost, potential side 
effects, weight gain, comorbidities, hypoglycemia risk and 
patient preference. Therefore chronic diseases like diabetes 
mellitus requires the design of new drugs with high 
specificity and efficacy in the treatment [3]. In the present 
study, PHD (Prolyl Hydroxyl Domain) Proteins hydroxylate 
the proline residues of HIF and regulates HIF and in an 
oxygen-dependent manner [4]. But under Hypoxic 
conditions hydroxylation of HIF results in dysregulation of 
HIF inducing inflammation of pancreatic beta cells leading to 
insulin resistance which is a major hallmark of type 2 
diabetes mellitus [5]. Inhibition of PHD3 activity by small 
molecule inhibitors leads to stabilization of HIF subunits 
providing a potential therapeutic strategy in the treatment of 
T2DM.  
PHD3 is the liver specific protein residing in the pancreas 
containing hypoxia response element (HRE) which is 
upregulated by HIF. HIF is a transcriptional controller that 
plays an important role in maintaining oxygen levels in 
pancreatic tissues. HIF subunits are regulated by PHD3 
protein by hydroxylating their proline residues [6, 7]. A 
recent study supported that HIF is required for normal β-cell 
function and reserve and that its dysregulation may cause to 
the pathogenesis of type 2 diabetes. Figure1 representing the 
biological pathway of PHD3 in type 2 diabetes mellitus. 
Inhibition of PHD3 regulates HIF levels under hypoxia which 
increases the insulin secretion suggesting the important role 
of HIF in regulating the β-cell amount and implicating PHD3 
as potential therapeutic target for the β-cell dysfunction of 
type 2 diabetes mellitus [5, 8].  
The present study was carried out for the identification of 
novel potential inhibitors against PHD3 as a therapeutic 
target for diabetes mellitus with a lower risk of side effects 
using computational approaches. In this study structure 
based virtual screening, molecular docking, MM/GBSA 
approach and ADME studies were together considered for 
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the development of new potential therapeutics against PHD3 in type 2 diabetes mellitus treatment. 
 
 
Figure 1. Biochemical pathway of PHD3 protein. Hypoxic conditions reduce the capacity of PHD3 to hydroxylate HIF, 
resulting in the dysregulation of HIF causing pancreatic inflammation leading to a state of insulin resistance results in 
type 2 diabetes mellitus. 
MATERIALS AND METHODS  
Homology modeling of PHD3 protein 
 Homology modeling is used to make a 3D model of the 
target protein as the structure of a protein is unknown or it 
is not determined by experimental techniques like NMR and 
X-ray. [9]. A known template sequence with good similarity, 
identity and e-score is required to align with the sequence of 
the target protein to generate homology model. The 5LBF A 
was selected as potential template by providing the FASTA 
sequence of PHD3 to the BLAST server. The sequence with 
the highest similarity and e-score is considered as a 
reference sequence (5LBF A) to produce a 3d homology 
model of PHD3 [10]. The alignment of both the sequences 
was operated in clustalX2 to find out the regions of 
similarity that represents the functional and structural 
evolution of sequences [11]. The homology model of PHD3 
was generated by using MODELLER9.9 software. Twenty 
(20) models were generated during the modeling, among 
these 3d structures of protein, the one with least modeler 
objective function (molpdf) was taken into the consideration 
for further refinement of 3d model and methodology. 
Energy minimization and simulation studies 
The homology modeling produces the 3d structure with high 
energy because of abnormal overlapping of nonbonding 
atoms of protein leading to severe steric clashes between 
residues of a protein. The refinement of protein is carried 
out using NAMD (Nanoscale Molecular Dynamics) and 
results visualized with VMD (Visual Molecular Dynamics). 
NAMD is a key molecular simulation software package to 
refine (energy minimization) the 3d structure of a protein 
with visualizing suite VMD [12]. The energy minimization of 
PHD3 in NAMD suite was carried out in a total of 100000 
steps and monitored by RMSD values with time units(fs). 
The refined protein is used for further in-silico operations 
and docking studies.   
Validation of PHD3 protein 
Validation of the 3d model of PHD3 is required to know the 
quality of the 3d structure. Various online protocols are 
employed to check the reliability of the 3d model. The 
quality of the 3d model is evaluated with ProSA, PROCHECK 
[13] (Ramachandran plot). The ProSA server was recruited 
to estimate the energy profile and to validate protein in 
terms of z-score. PHD3 protein is validated with Procheck 
program in pdbsum server delivers Ramachandran plot 
which gives the favored regions of residues in accordance 
with stereochemistry.  
Active site prediction 
Predicting the potential active site residues of the target 
protein is an important outcome in drug discovery. Binding 
site residues of the protein bind to the ligand residues with 
its hydrogen bond donors and acceptors [14].  The Active 
site of PHD3 protein was analyzed with bioinformatics tools 
like SiteMap (Schrodinger), literature and manual 
correlation technique. The reported 3d structure of template 
5LBF was retrieved from pdbsum server consisting of 224 
amino acid chain which is reported with the ligand UN9 (N-
[1-Chloro-4-hydroxy isoquinoline-3-Y1 carbonyl] glycine), 
with the molecular formula: ClH9ClN2O4 is taken into the 
consideration and the active site residues (pdbsum-ligplot) 
correlated to PHD3 protein sequence for active site 
prediction. The residues obtained by manual correlation are 
considered as active site residues responsible for functional 
evolution of PHD3. The nature of active site regions of 
protein is analyzed by SiteMap in Schrodinger suite which 
gives information about volumes of acceptor and donor 
regions of binding pockets in angstrom units [15,16]. 
Virtual screening and molecular docking 
Virtual screening of chemical libraries is a quick and 
accurate technique to identify novel and potential leads in 
the drug discovery process. Asinex ligand data set of small 
molecules are selected to screen with PHD3 protein using 
Glide tool in maestro Schrodinger suite for identification of 
lead molecules. Ligands were prepared with the help of 
Ligprep module in Schrodinger software with an applied 
force field of OPLS_2005 in order to generate its 3D 
coordinates from 1D. Asinex databank with 10000 molecules 
was subjected to the Ligprep in maestro Schrodinger suite 
results optimized isomers. These molecules, in turn, are used 
as an input for virtual screening. Virtual screening of Asinex 
small molecules were carried out under HTVS (High 
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Throughput Virtual Screening), SP (Standard Precession) 
and XP (Xtra Precession) modes of filtering to results lead 
molecules. The final lead molecules were prioritized based 
on their glide score, glide energy and ADME properties [17]. 
Pharmacology 
Elucidation of Pharmacology of new lead molecules obtained 
from molecular docking is an essential protocol to study 
pharmacokinetic properties (ADME) which are used to 
estimate druggability of new chemical entities. ADME 
properties of best fit molecules are predicted using Qikprop 
[18] module in Schrodinger suite. 
Binding free energy calculations 
The binding free energies of protein-ligand complex are 
calculated using Prime MM-GBSA approach (19). The 
Binding free energies of top lead molecules with protein 
receptor calculated using Prime- MM/GBSA method with an 
applied force field of OPLS_2005 in maestro Schrodinger 
suite. 
 
Binding free energy of complex (receptor to ligand) 
calculated using the following equation 
ΔGbind = G (ligand-receptor) - (Gprotein + Gligand) 
RESULTS AND DISCUSSION 
Homology modeling and model refinement 
Target protein PHD3 with accession id Q9H6Z9 with 239 
amino acid residues was selected from UniProt from Server 
Expert Protein Analysis System (ExPASy SWISS-
PROT/TrEMBL) which is a bioinformatics data source of 
proteins [20]. Homologous template 5LBF A is selected from 
BLAST and J-Pred online servers by submitting target 
protein sequence in Fasta format as an input. Both the 
servers provided similar templates for target PHD3 protein 
based on parameters sequence position and secondary 
structure prediction respectively. Template 5LBF A obtained 
from BLAST has an e-score of 6e-110, 93% query coverage, 
and 65% of identity. J-Pred also results 5LBF A as template 
with an e-score of 4e-86. The conserved domain of the PHD3 
protein retrieved from BLAST server shown in Figure2. The 
3d homology model of PHD3 protein was generated using 
MODELLER9.9 which it uses alignment of query sequence 
with its homologous template 5LBF A sequence. The 
sequence alignment of PHD3 to that of template 5LBF A is 
visualized with discovery studio4.1 shown in Figure3. 
Twenty (20) 3d models are generated, among this group of 
models, one of the model consists of least modeler objective 
function value 1213.63(molpdf) which is taken into 
consideration for further computational evaluation [21]. 
The secondary structure of PHD3 shown using pymol tool 
(Figure4).  
Energy minimization of PHD3 protein was carried out in 
NAMD-VMD interface. Simulation studies were applied for 
the energy minimization of PHD3 protein. Energy 
minimization was carried out in NAMD software with a 
CHARMM-AMBER force field [22]. A total of 100000 cycles 
of the energy minimization was carried out using NAMD 
module. The protein coordinates are analyzed with RMSD 
values. The RMSD values observed during simulation studies 
of PHD3 protein represented with a graph shown in Figure5. 
The RMSD values observed between 1.0 to 1.2Å where it 
reaches energy minima at averaged RMSD value of 1.10 Å 
which become remain constant with time units (1001-2003 
fs) where RMSD is a measure of equilibration and protein 
flexibility.
 
 
Figure 2. The conserved domain of PHD3 protein was saved from the BLAST server by submitting fasta sequence as an 
input. 
 
Figure 3. Sequence alignment of Residues of human PHD3 protein with the residues of its homologous template 5LBF is 
executed in discovery studio 3.5. Identical residues are highlighted with orange color, the residues fall in the strong 
zone are colored with blue, weak zone residues are indicated with green color, whereas the residues showed in pink 
color are not matched residues.  
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Figure 4. The secondary structure of PHD3 consists of 
6α-helices represented in spirals and 3 beta sheets. The 
conserved part of the protein exposed with the pink 
color. C-terminal and N-terminal end of the 3d structure 
indicated with green and red color respectively. 
 
 
Figure 5. The graph representing the RMSD values of 
various energy states at different intervals of time as a 
plot of RMSD values against time frames. The averaged 
RMSD value of 1.10Å is observed between 1001-2003 
time frames.  
 
Validation of PHD3 protein 
The reliability of PHD3 model evaluated with standard 
validation protocols. Ramachandran plot of PHD3 protein is 
retrieved from PROCHECK in pdbsum server. The steric 
clashes between psi-phi angles of amino acid residues of 
protein were explained with a contour plot. Ramachandran 
plot of PHD3 protein consists a total of 99.6% of residues 
falls in the core region of the plot which is a sterically free 
zone indicating that PHD3 is a reliable model to continue for 
further computational studies. The detailed contour plot of 
allowed and disallowed regions represented with 
Ramachandran plot shown in Figure6 [23]. The overall 
model quality of PHD3 is evaluated by using ProSA [24] in 
terms of z-score. The ProSA analysis of PHD3 provides a 
structural similarity with a z-score of -5.8 signifying the 
good quality of protein which falls in the region of similar 
groups of structures of protein determined from X-ray and 
NMR showed in the ProSA with light blue and blue color 
respectively shown in Figure7.  
 
Figure 6. Ramachandran plot of PHD3 is saved from 
Procheck server. The overall plot of PHD3 Protein 
consists of 99.6% of residues lies in the sterically free 
zone, that is favored region, which reporting good 
quality of the 3D model.  
 
 
Figure 7. The ProSA plot of PHD3 is showing a z-score of 
-5.8 representing the good quality of protein structure. 
The regions with blue and light blue colors are about the 
groups of similar structures of protein, determined from 
NMR and X-Ray methods respectively. The black spot 
resembling the PHD3 pdb. 
 
Identification of the binding site of PHD3 protein  
The binding site of PHD3 is identified by the manual 
correlation technique, SiteMap and other computational 
tools. The Ligplot of known template 5LBF taken from 
Pdbsum server and consists the ligand named UN9 (N- [1-
Chloro-4-hydroxy isoquinoline-3-Y1 carbonyl] glycine) 
showing the interactions with the residues Gly215, Lys216, 
Glu217, Asp254, Ile256, Met299, Tyr303, Tyr310, His313, 
Asp315, Ile327, Tyr329, Leu349, His374, val376 and Arg383. 
These residues of 5LBF were manually correlated to the 
residues of the target sequence in ClustalW Omega software 
by means of multiple sequence alignment in order to identify 
the active site residues of PHD3 protein (Figure8). The 
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putative binding regions of the PHD3 protein are identified 
using SiteMap with an applied force field of OPLS_2005 in 
Schrodinger suite. The SiteMap of PHD3 provides 
information about the nature of binding of regions (Figure9). 
SiteMap identifies potential binding regions by correlating to 
active site cavities that are most likely participates in 
protein-ligand binding and the area of binding pockets 
measured in terms volume in angstrom units as listed in 
Table1[25].  
Table 1. The putative active site, nature of binding 
regions that bind with ligand hydrophobic and 
hydrophilic regions are calculated from the SiteMap in 
Schrodinger software. 
Sitemap cavity Region name Volume (Å) 
1 Hydrogen acceptor 148.12 
2 Hydrogen donor 226.99 
3 Hydrophilic 387.06 
4 Hydrophobic 56.57 
 
 
Figure 8. Identification of active site residues of PHD3 protein by manual correlation of template 5LBF residues with 
that of PHD3 residues using ClustalW, indicated with green and yellow colors respectively. 
 
Figure 9. The putative active site of PHD3 protein identified using the SiteMap tool in Schrodinger suite. The blue color 
region of the protein is indicating that hydrogen acceptors area; the red color region is displaying that hydrogen donor 
area. The Hydrophobic region of the active site is shown in maroon color. Grey colored dots represent the cavity of the 
putative active site of the protein. 
Virtual screening and docking analysis 
Structure based virtual screening is an important technique 
for obtaining lead molecules from data sets chemical 
structures to act against the biological target. PHD3 protein 
is screened with a data set of ligand library Asinex consisting 
of 10000 molecules. A three dimensional grid is generated by 
Glide module in Schrodinger suite using active site residues 
of PHD3 protein as input for virtual screening studies with 
the dimensions of 32 Å x32 Å x32Å and 80 Å x80 Å x80Å with 
a box size of 1.00Å. The Ligand preparation was carried out 
using Ligprep [26] application in Schrodinger suite for 
molecules of Asinex database in order to generate 
energetically favorable structures and its atomic coordinates 
tautomers and ionic isomers of ligand molecules to avoid 
poor interactions to PHD3 protein in docking. These 
generated ligands used as an input source for virtual 
screening [27]. The Ligprep out file of Asinex database 
consisting of 31820 molecules is subjected to HTVS mode of 
screening which filters a large number of molecules in part of 
docking with 5 poses per ligand. 10% (3182) of the 
molecules are comes out from the HTVS mode of screening 
based on glide screening functions. These 3182 molecules 
are redocked under SP (Standard Precession) mode in order 
to produce more effective ligands which results in 318 
molecules which are in turn redocked in XP (Extra 
Precession) mode to filter ten percent of molecules from SP 
docking. The final out file of XP results in 32 hit molecules 
which are considered as best fit molecules for PHD3 protein. 
[21, 28]. The screened best fit molecules are ranked based 
on binding free energies (MM/GBSA), docking scores and 
glide energy as tabulated in Table2. The four lead molecules 
M1-M4 are identified as potential inhibitors based on 
binding free energies (MM/GBSA), docking scores, glide 
energies and hydrogen bond interactions. The binding poses 
of M1-M4 with PHD3 active site are visualized in three 
dimensional patterns using discovery studio4.1 as shown in 
Figure10. The identified new lead molecules M1-M4 are 
consistently binding to the residues Lys111, Glu216, Glu217, 
Glu220, and Tyr112 of PHD3 protein by making hydrogen 
bonding interactions indicating their binding specificity. 
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Table 2. Structures of lead molecules M1-M4 identified from virtual screening of Asinex dataset with PHD3 protein and 
their intermolecular interactions; bond distances prioritized with glide score, glide energy and binding free energies. 
S.No Structure of lead molecule Glide 
score 
Glide energy 
(kcal/mol) 
Intermolecular             
interactions 
(H-Bonds) 
Bond 
distance(Å) 
Prime-MM/GBSA, 
∆GBind (kJ/mol) 
M1 
 
-8.71 -34.38 M1::LYS-111 
M1::LYS-223 
M1::GLU-220 
M1::GLU-220 
4.38 
2.43 
3.47 
1.30 
-37.55 
M2 
 
-7.13 -23.59 M2::GLU-217 
M2::GLU-217 
M2::GLU-220 
M2::TYR-112 
2.49 
1.51 
2.98 
3.47 
-32.50 
M3 
 
-6.87 -33.10 M3::ARG-218 
M3::LYS-222 
M3::LYS-224 
M3::ALA-221 
M3::ASN-140 
3.00 
2.56 
2.71 
1.33 
1.62 
 
 
-31.28 
M4 
 
-6.18 -30.43 M4::TYR-112 
M4::LYS-111 
M4::LYS-111 
M4::GLU-220 
3.17 
4.51 
4.54 
4.31 
-46.61 
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M1 (a)                                                         M1 (b) 
 
M2 (a)                                                          M2 (b) 
 
M3 (a)                                                               M3 (b) 
 
M4 (a)                                                                 M4 (b) 
Figure 10. The binding orientations of best fit molecules M1-M4 identified from virtual screening. The protein showed 
in solid ribbon manner with green color and ligand displayed as ball-stick form. The amino acid residues are 
represented in the form of sticks with blue color. The intermolecular hydrogen bonds are denoted with light green 
dotted lines and pi-pi interactions are shown with orange color lines. The 2d ligand interaction figures retreived from 
schrodinger suite.  
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Binding free energies and ADME studies 
Binding free energies of identified new lead molecules are 
calculated using the prime-MM/GBSA tool in Schrodinger 
suite. Binding free energies of newly identified lead 
molecules with protein receptor are calculated using OPLS-
AA (2005) force field and GBSA continuum solvent model. A 
lead molecule M4 from final hits showing the good binding 
free energy of -46.61 kJ/mol with a 100% human oral 
absorption which consists 1H-pyrrolo[2,3-c]pyridine scaffold 
acts as novel pharmacophore moiety may be considered as 
more potent for the inhibition of PHD3 against T2DM. All the 
four identified novel lead molecules M1-M4 are showing the 
permissible binding free energy values in range of -46.61 to -
31.28 kJ/mol and showing consistent interactions with the 
residues Lys111, Tyr112, Glu217 and Glu220 which are 
responsible for their specific binding affinity. The docking 
score, glide energy, hydrogen bond interactions and 
MM/GBSA binding free energies are important factors to 
design potential inhibitors against PHD3 protein. The 
pharmacokinetic properties (ADME) of identified lead 
molecules are calculated using Qikprop in Schrodinger suite 
to estimate druglike activity. All the four lead molecules are 
following the Lipinski rule of five, Jorgensen rule of three and 
existing within the range of acceptable CNS ranges and 
showing permissible ranges of human oral absorption 
(Table3). [29].  
 
Table 3. The ADME properties are calculated using QikProp module. All the identified leads M1-M4 are satisfying the 
pharmakokinetic properties in the permissible range of ADME values. 
S. No CNS m.wt Donor 
Hb 
Acceptor 
Hb 
Q plog 
Po/w 
Q plog 
BB 
% of Human 
oral 
Absorption 
Rule of 
three 
Rule of 
five 
M1 -2 415.45 3.0 8.50 0.55 -1.43 46.06 1 0 
M2 0 330.42 3.0 5.75 1.58 -0.47 79.10 0 0 
M3 1 389.43 2.0 6.50 3.32 -0.27 88.19 0 0 
M4 0 376.45 1.00 6.25 3.79 -0.473 100 0 0 
 
 
CONCLUSION 
In this study, PHD3 has been considered as a therapeutic 
drug target against type 2 diabetes mellitus. The homology 
model of the molecular target PHD3 protein was generated 
by MODELLER9.9 program for structural elucidation. The 
refinement of 3d model was done through energy 
minimization in NAMD software. Virtual screening was 
carried to find out new molecular entities to act against the 
binding site of PHD3. A total four potential leads M1, M2, M3 
and M4 are identified as novel chemical entities against 
target protein which are prioritized based on glide score, 
glide energy, binding free energies (MM/GBSA), and % 
human oral absorption (Bioavailability). The lead molecule 
M4 is showing maximum bioavailability (100%), predictable 
binding free energy (-46.61kJ/mol) from Prime-MM/GBSA 
and contain 1H-pyrrolo[2,3-c] pyridine moiety as it acts as 
pharmacophore which is more probable to design as potent 
inhibitor. The results showing that the identified lead 
molecules M1 to M4 are showing specific binding with the 
residues Lys111, Tyr112, Glu217, and Glu220 and satisfying 
the druglikeness by showing permissible ranges of ADME 
properties. The whole procedure gave insights into the 
structure based approach to design potential therapeutics 
against PHD3 for type 2 diabetes mellitus.  
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